1.25-2.5mg/day
Here's some more side effect info:
Blood pressure should be monitored periodically in all patients receiving bromocriptine, especially during the first few days of therapy with the drug. Particular care should be exercised in patients receiving other hypotensive drugs concomitantly. Decreases in blood pressure frequently have been reported during the puerperium independent of drug therapy, and some women have developed bromocriptine-induced hypotension or, rarely, hypertension, including hypertensive crisis. (See Cautions: Cardiovascular Effects.) Because of the risk of this and other potentially serious adverse effects, which may be fatal, use of bromocriptine for the prevention of postpartum lactation no longer is recommended.Patients should be warned that bromocriptine may impair their ability to perform activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle).Hepatic, hematopoietic, cardiovascular, and renal function should be evaluated periodically in patients receiving prolonged therapy with bromocriptine, as in the treatment of parkinsonian syndrome. The safety of long-term bromocriptine therapy for periods longer than 2 years at dosages used in the treatment of parkinsonian syndrome has not been established. Since high dosages of bromocriptine may be associated with confusion and mental disturbances, the drug should be used with caution in patients with parkinsonian syndrome who manifest mild degrees of dementia. Bromocriptine therapy, alone or combined with levodopa, has been associated with visual or auditory hallucinations in patients receiving the drug(s) for parkinsonian syndrome; hallucinations usually resolve following dosage reduction, but discontinuance of bromocriptine may occasionally be necessary. Rarely, after high dosages, hallucinations may persist for several weeks following discontinuance of the drug.Bromocriptine should be used with caution in patients with impaired liver or renal function, since safety and efficacy of the drug in these patients have not been definitely established. Dosage of bromocriptine may have to be reduced in patients with impaired liver function.Bromocriptine should also be used with caution in patients, particularly those with parkinsonian syndrome, who have a history of myocardial infarction and a residual atrial, nodal, or ventricular arrhythmia.The relative efficacy of bromocriptine therapy versus surgery in preserving the visual fields in patients with hyperprolactinemic disorders is not known. Patients with rapidly progressing visual field loss should be evaluated by a neurosurgeon.Patients receiving bromocriptine for hyperprolactinemic disorders associated with macroadenomas and those who have undergone transsphenoidal surgery should be advised to report to their physician any persistent, watery nasal discharge that occurs during therapy with the drug, since this may be a sign of CSF rhinorrhea. (See Cautions: Nervous System Effects.)Patients receiving long-term (e.g., 6–36 months), high-dose (e.g., 20–100 mg daily) bromocriptine therapy should be observed for pulmonary changes such as infiltrates, effusion, and thickening of the pleura since these effects have occasionally occurred.Patients with acromegaly should be monitored for cold-induced digital vasospasm during bromocriptine therapy. Vasospasm usually resolves following a reduction in dosage and may be prevented by keeping the fingers warm. Patients with acromegaly should also be monitored for signs and symptoms of peptic ulcer during bromocriptine therapy; such signs and symptoms should be thoroughly evaluated and appropriate therapy instituted if necessary. GI bleeding from peptic ulcers, sometimes fatal, has occurred during therapy with the drug in patients
